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Abstract
The increasing efficacy of cancer therapeutics means that the timespan of cancer therapy administration is undergoing
a transition to increasingly long-term settings. Unfortunately, chronic therapy-related adverse health events are an
unintended, but not infrequent, outcome of these life-saving therapies. Historically, the cardio-oncology field has
evolved as retrospective effort to understand the scope, mechanisms, and impact of treatment-related toxicities that
were already impacting patients. This review explores whether current systemic approaches to detecting, reporting,
tracking, and communicating AEs are better positioned to provide more proactive or concurrent information to
mitigate the impact of AE’s on patient health and quality of life. Because the existing tools and frameworks for
capturing these effects are not specific to cardiology, this study looks broadly at the landscape of approaches and
assumptions. This review finds evidence of increasing focus on the provision of actionable information to support
long-term health and quality of life for survivors and those on chronic therapy. However, the current means to assess
and support the impact of this burden on patients and the healthcare system are often of limited relevance for an
increasingly long-lived survivor and patient population.
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Background
The evolution of the field of cardio-oncology is emblem-
atic of an increasing awareness of the scope and impact
of cancer therapy-related cardiac toxicities and a desire
to limit these effects in both current and future patients.
The literature is extant with study of the unintended and
delayed but potentially severe cardiac effects of anthra-
cyclines (as used for decades to treat some childhood
cancers, breast cancer, etc.) [1–7]. Unfortunately, even
for novel therapeutic approaches such as checkpoint
inhibiting immunotherapy, the community again finds
itself facing unanticipated and uncertain cardiac adverse
events (AE) associated with the primary therapy [8, 9].
This phenomenon begs the questions of whether the
cardio-oncology community specifically and cancer care
community broadly (research, drug development, regula-
tory review, clinical practice, patients and their advo-
cates) have improved in their ability to anticipate and
support treatment-related AEs that may manifest in
long-term cancer survivors.
The nexus of increasing therapeutic efficacy and the
reality that 40% of the population will be diagnosed with
cancer in their lifetime creates an important new public
health challenge [10, 11]. The timespan of cancer ther-
apy administration, care, and outcome is shifting from
primarily acute treatment settings to a broad range of
chronic adjuvant therapy and survivorship settings
[12–14]. Treatment-related AEs may span in severity
from potentially lethal cardiotoxicities to less dire but
still debilitating systemic events, including fatigue,
gastrointestinal issues, skin inflammation, and neur-
opathy [15–21]. The cumulative effect of these out-
comes can vary considerably from patient to patient.
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AEs can inhibit the curative value of a therapy if
these effects impede a patient’s ability or willingness
to continue therapy [22]. Modulatory factors such as
variable treatment adherence rates, drug-drug interac-
tions, access to care, and patient comorbidities result
in a range of patient experiences and healthcare system
demands [23]. Even for a specific treatment-related AE
(e.g., treatment of aromatase inhibitor–induced chronic
pain or approaches to monitoring ejection fraction
changes associated with anthracycline cardiotoxicity), the
nature of the supportive approaches that are adopted may
vary considerably from site to site [24, 25].
Observational studies and health record analyses dem-
onstrate that cancer treatment-related AE (both moder-
ate and severe) can also degrade patients’ or survivors’
overall health status, cause financial strain, and limit
their ability to meet family obligations, work, or pursue
fitness or hobbies [12, 23]. Supportive care to ameliorate
AEs may require patients to procure a broad range of
pharmacologic treatments, undergo monitoring and test-
ing, change diet and exercise practices, seek out rehabili-
tation services or pursue complementary alternative
medicine approaches like acupuncture [26–30]. In sum,
the impact of AEs on long-term cancer patient and sur-
vivor quality of life are broad and diverse in their mani-
festation (Fig. 1).
Ideally, of course, our ability to predict, limit, support,
and/or prevent cardiac and other AE associated with
cancer therapy would evolve in parallel with therapy de-
velopment and approval. In practice, however, the
growth of the cardio-oncology field has been a function
of the many medical epidemiology and cohort studies,
practitioner case reports, and innovative translational
and mechanistic studies initiated only after many de-
cades of observing the profound manifestation of these
toxicities as morbidity and mortality in cancer survivors.
The cancer care community has an opportunity and ob-
ligation to transition towards a more proactive stance on
the collection and use of AE information to improve pa-
tient outcomes and quality of life.
In order to support the growing population of survi-
vors and patients receiving chronic cancer therapy, a
broad set of stakeholders (including drug developers,
regulators, insurers, clinicians, patients and their fam-
ilies) will require actionable and integrated risk and
benefit information to support long-term health and
quality of life. However, a successful transition towards
greater proactivity and broadened time horizons for such
assessments will require more than an aspiration. It will
depend heavily on the consistent use of relevant metrics
and robust data integration frameworks.
This paper explores comprehensive literature reviews
to evaluate some of the contemporary systemic measures
and frameworks used to assess and communicate
potential AEs and their impact on patients. Because the
systematic approaches to detecting, reporting, integrat-
ing, and acting upon on cancer therapy AEs are neither
limited to nor unique for cardiovascular AEs – these
reviews consider a breadth of endpoints in their discus-
sions and analyses. The specific relevance of these
approaches for aiding cardiologists, oncologists, and
others in providing support to patients and survivors
will be addressed.
Data sources and drivers
Before any oncology drug moves into clinical practice in
the United States, the balance between acceptable AEs
(risk) and efficacy (benefit) is influenced and assessed by
pharmacologic drug design, nonclinical testing, clinical
trials, and regulatory review, all of which are major
investments spread across the private and public sectors.
During this process, the risk:benefit ratio for the therapy
is calibrated (by the drug developer and regulatory
reviewers) against the lethality of the target cancer [31].
Broadly speaking, these approaches provide an accepted
and protective means of balancing anticipated AEs with
efficacy in the patient population [32]. Interindividual
variability in response to treatment, heterogenous tumor
types, and limited study durations have, however, been
cited as challenges in the generation of population-level
and/or individual patient-level biological outcomes [33].
As a result, investment in enhancing preclinical predic-
tivity is a significant area of growth. The biomedical
research community is pursuing the adoption of novel
preclinical experimental platforms, innovative preclinical
and clinical trial designs, the use of comparative
effectiveness methods, and enhanced collection of
patient-reported AE data to enhance the predictive rele-
vance of premarket safety and efficacy data [34–38]. It is
clear, however, that the current effort and investment in
nonclinical oncology safety studies and clinical trials
generates data that are more highly focused on and pre-
dictive of some outcomes (e.g., acute organ toxicities)
than others (e.g., chronic pain or delayed onset events
such as cardiac damage) [38, 39].
On the other end of the drug development horizon,
and at the genesis of the field of cardio-oncology, are
data and experiences from patients outside of a clinical
trial or nonclinical study setting. This arena is now often
referred to as the source for ‘real world evidence’
(RWE). RWE can be defined as “information on health
care that is derived from multiple sources outside typical
clinical research settings, including electronic health
records (EHRs), claims and billing data, product and dis-
ease registries, and data gathered through personal
devices and health applications” [40]. The cancer com-
munity at large is actively exploring opportunities to
leverage this type of approach across broad cancer
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therapy classes and patient demographics. These efforts
seek to use RWE in relation to a marketed drug or set of
therapeutic approaches to promote a “learning health-
care system” (LHS) in the United States [40–42]. The
LHS concept, initiated by the Institute of Medicine in
the early 2000s, promotes the generation of “the best
evidence and to apply that evidence to the healthcare
choices that each patient and provider make in
Fig. 1 Schematic pathway linking cancer treatment, survivorship, adverse events, and quality of life (Original figure by Syril Pettit)
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collaboration; to drive the process of discovery as a nat-
ural outgrowth of patient care; and to ensure innovation,
quality, safety, and value in health care.” [43]
Although RWE has been instrumental as a primary
evidence base for delayed cardiac effects of cancer ther-
apy, its feasibility as an operational means to realize a
more iterative and interconnected healthcare system at
large is less clear. The means to integrate RWE as a
complement to regulatory safety evaluation via random-
ized controlled trials (RCTs) and/or as a means of gener-
ating novel efficacy, safety, or use information for
marketed drugs remains uncertain [40–42]. For example,
Sherman et al. (2017) cite the potential for RWE (e.g.,
postmarket surveillance or postmarket trials) to help re-
fine dose-setting, subpopulation identification, and
long-term safety considerations for novel cancer thera-
peutics that receive expedited initial approval. The
model they describe, however, does not truly expand the
traditional approach to drug evaluation and retains the
longstanding emphasis on standard safety/efficacy end-
point collection and regulator-mediated evaluation and
decision making. Novel clinical trial designs and settings
(e.g., the National Institutes of Health Collaboratory),
large-scale health record analysis (e.g., Million Veterans
Program), and new patient-engaged networks (e.g.,
PCORnet) have also been cited as potential opportun-
ities to generate RWE [44–46]. As these are all relatively
new programs (less than 3 years), their impacts are not
yet defined. Ultimately, the success and novelty of any
RWE approach to informing healthcare will rely upon
the generation of credible, fit for purpose, and otherwise
unavailable information as well as viable channels to dis-
seminate and use this information. If indeed RWE is
intended to enhance the value of health data (AE-driven
or otherwise) to a range of stakeholders, a more nuanced
and diverse evaluation of stakeholder needs will be
required.
To this end, approaches to better engage patients as the
primary stakeholder abound. The movement to provide
“patient-centered care” with “shared decision making” is in
part driven by a desire to enhance therapeutic adherence
and efficacy by engaging patients with understandable in-
formation about the benefits, risks, costs, and logistics of
their treatment [47–52]. This too is a challenging space as,
not unexpectedly, preferences for balance of QoL versus
length of life vary from patient to patient (and can vary dur-
ing the course of therapy) [53, 54]. As such, the measurable
impact of new patient-centered interventions is an area of
active study with regard to the role of patient satisfaction
on therapeutic adherence and health outcome [55, 56]. Al-
though the concepts of patient-centered care are widely
embraced conceptually, the way in which these elements
are pragmatically incorporated into practical care decisions
or data generation incentives remains loosely defined [52].
Aligning information and patient need
Despite both the conceptual objectives described in the
prior section and the considerable practical experiences
in the cardio-oncology arena, to date, there has been
minimal systematic assessment of the alignment of avail-
able integrative approaches in the published literature
with the demographic and temporal realities of an
ever-growing cancer survivor population. This review fo-
cuses on the source data and assumptions relating to the
use of AEs as part of integrative evaluations used to in-
form therapy-related decisions and patient care for long
term treatment or survivorship settings. As the value of
these approaches will depend upon their flexibility and
external validity, this study includes but will not be lim-
ited to cardio-oncology specific applications.
Approach to reviewing the literature
The discussions below reflect the integration of two dis-
tinct but complementary comprehensive literature re-
views on the use of AE data in characterizing the impact
of cancer therapy on long-term cancer patients and sur-
vivors. The first review focuses on economic modeling
approaches as these were the primary format for inte-
grated “valuation” of the impact of treatment-related
AEs before the year 2016. This publication is the first
systematic evaluation of the variance in these method-
ologies with a specific emphasis on their underlying
assumptions and data sources. The review evaluates the
diversity of AEs and costs evaluated, the range of popu-
lations studied, and the relevance of these metrics
towards informing and supporting patient quality of life.
The second review moves forward in time to recognize
the 2016 release of novel integrated ‘value frameworks’
by several professional societies including American
Society of Clinical Oncology and the European Society
of Medical Oncology. These frameworks were proposed
as novel, integrative tools to combine toxicity, efficacy,
cost, and other factors deemed critical for treatment and
supportive care decision-making. The second literature
review identifies the ways in which the recent flurry of
integrative value frameworks has (or has not) improved
on pre-2016 approaches and the likelihood that these
frameworks will support enhanced access to actionable
information for patients and clinicians.
Specifically, the reviews address two foundational ap-
proaches in the context of long-term cancer therapy and
survivorship:
 Review 1: How have economic models been designed
and populated to measure the impact of treatment-
related AEs on cancer patients and the healthcare
system?
 Review 2: What recommendations have been
promoted to improve the quality and/or relevance of
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AE-related input data for cancer care value
frameworks?
The results of each literature assessment follow below
individually and then are integrated to define common
approaches, key strengths and limitations, and consensus
recommendations for future needs. The specific rele-
vance to the cardio-oncology arena is addressed.
Review 1: Cost as a proxy for AE impact –
Integrative assessments before 2016
Over the last 10 years, quantitative efforts to capture the
impact of treatment-related adverse events have primar-
ily taken the form of economic studies and
quality-adjusted life-year (QALY) models and projec-
tions These efforts are largely aimed at economic, regu-
latory, and/or policy audiences. The few available
estimates of the cost of purchasing and administering
cancer therapy, monitoring health while on therapy or
after, and managing AE detection and care, point to a
major societal investment—as much as $120 billion and
growing annually [23, 57]. In the cardio-oncology arena,
the cumulative direct costs of supportive care for
delayed cardiac effects are difficult to source. However,
several studies have looked at the cost effectiveness of
interventions such as pre-emptive left ventricular ejec-
tion fraction screening and determined that it is likely to
be a cost-effective measure towards detecting dysfunc-
tion before it translates into heart failure [58].
Almost irrespective of the cost figures themselves, the
exercise of estimating ‘total’ cost associated with the
long-term effects of therapy allows for a thoughtful
examination of a range of clinical, lifestyle, financial, so-
cial, and temporal elements that extend well beyond the
scope of the typical U.S.-based drug safety assessment.
In the U.S., the Food and Drug Administration (FDA) is
not mandated to consider financial impacts when mak-
ing regulatory approval decisions for oncology drugs and
thus does not consider cost factors in its decision mak-
ing although such approaches are routinely used in
evaluating drugs in Europe [59, 60]. The use of cost as a
means of capturing the totality of treatment-related AEs
on patients is an approach subject to some debate in
economic, clinical, patient, and medical ethics communi-
ties [61, 62]. For example, in the context of anthracycline
induced cardiac toxicity, the ‘value’ of dexrazoxane as a
cardio-protective agent has been an ongoing focus for
studies seeking to align data around its protective ef-
fects, safety, cost, and societal willingness to pay [63–
66]. Despite the sometimes conflicting outcomes, these
studies have a vital role in informing an evolving
landscape of methods that integrate diverse data of
relevance for characterizing long-term cancer patient
care and support.
A 2013 review covered some of these topics as they re-
lated to studies between 1999 and 2009 with a primary
focus on whether QoL, multiple dose administration,
and multiple AEs were considered in the cost assess-
ment [67]. We have extended this review by incorporat-
ing material from the years 2007–2017, enhancing the
focus on the source of AE data and AE terminology
(ontology), characterizing the target patient population
to whom the cost/risk predictions apply, and exploring
assumptions around the cost of AEs and related sup-
portive services. Although these issues span across the
globe, for purposes of limiting the healthcare delivery
context referenced in this analysis, the discussions here
are focused primarily on the United States. Specifically,
the review below asks: How have economic models been
designed and populated to measure the impact of
treatment-related AEs on cancer patients and the health-
care system?
Search strategy
A semi-systematic search of articles between 2007 and
2017 was conducted using the following databases:
PubMed, Web of Science, CINAHL Plus with Full Text,
and EconLit. Additional studies were identified through
a manual search of references in relevant articles (snow-
balling) and evaluation of resources from leading organi-
zations in the cancer care arena in the United States
(e.g., ASCO). This research focused on those studies
which specifically seek to characterize the costs (eco-
nomic, social, logistical) of managing and treating
adverse effects of oncologic therapy. The search terms,
exclusion criteria, and Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses [PRISMA] diagram
detailing the literature procurement, filtering, and review
strategy are available as online supplemental materials
(Additional file 1: Table S1-Table S2, Additional file 2:
Figure S1). After comprehensive search, 631 unique cita-
tions were identified, 49 were deemed eligible for full
text review, and 27 were deemed fit for this analysis. A
summary of key findings follows below.
Results
The results of this structured review (2007–2017) pro-
vide insight into both the procedural means and situ-
ational assumptions around defining the costs of AEs
associated with oncologic therapy [68–94]. The studies
covered a broad range of therapeutic drug classes, can-
cer types, and patient populations. The major method-
ologies used in the 27 studies reviewed were: a)
mathematical modeling (Markov models) using histor-
ical data and assumptions around the probability that a
hypothetical patient would move across different states
of disease, health, and death at various points in their
care, b) estimations of the hypothetical total cost of care
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in support of AE based on compilations of diverse sets
and sources of data, c) prospective collection of AE inci-
dence, treatment, and cost information for actual pa-
tients, or d) meta-analyses of other published cost
studies. The studies employed one of two general ap-
proaches: estimation of the total cost of a therapeutic re-
gime (drug costs, clinical visit costs, adverse effect costs,
etc.) or assessment of the cost of one or more specific
AEs associated with a designated cancer therapy. The
methods for representation of the cost assessment varied
across the studies and included calculation of additional
quality adjusted life years (QALY)s relative to total treat-
ment cost, incremental cost to avoid a particular AE,
total accumulated costs during a given treatment period
(primary treatment costs and AE-related costs), total ac-
cumulated costs to treat AE only, and costs per
progression-free life-year (PFLY).
The authors looked across the 27 studies to assess
their respective approaches assessing and sourcing cost,
adverse event, quality of life, and patient demographic
information. The specific treatment of these issues in
each of the 27 articles reviewed for this study is available
as Additional file 1: Table S3-S7. The analysis demon-
strated that, despite the differences in the approaches
and focus across these articles, several consistent themes
and trends were evident (Table 1). As will be discussed
further in Results, these themes point to systemic limita-
tions in the availability of patient relevant and externally
valid data sources and approaches.
Review 2: 2016 value frameworks – Better tools
for Cancer care decision making?
Beginning in 2016, the practice of integrative therapy
impact assessment took a significant conceptual step for-
ward with the release of five major “value frameworks.”
Value frameworks were designed to inform policy deci-
sions as well as pragmatic therapy choices by clinicians
and patients for a broad range of cancers, patient demo-
graphics, and therapy classes. They aim to integrate data
on efficacy, safety (AEs), patient QoL, and, in some cases,
cost for specific therapeutic modalities [95–99]. Specific-
ally, the 2016 frameworks and their self-proclaimed objec-
tives are as follows:
 American Society of Clinical Oncology (ASCO) Value
Framework: “A framework that would enable a
physician and patient to assess the value of a
particular cancer treatment regimen given the
patient’s individual preferences and circumstances”
[95].
 European Society for Medical Oncology’s (ESMO)
Magnitude of Clinical Benefit Scale (MCBS): “The
ESMO-MCBS is an important first step to the crit-
ical public policy issue of value in cancer care,
helping to frame the appropriate use of limited pub-
lic and personal resources to deliver cost effective
and affordable cancer care” [100].
 Institute for Clinical and Economic Review (ICER)
Value Assessment Framework: “Ultimately, the
purpose of the value framework is to form the
backbone of rigorous, transparent evidence reports
that, within a broader mechanism of stakeholder
and public engagement, will help the United States
evolve toward a health care system that provides
sustainable access to high-value care for all patients”
[98].
 Memorial Sloan Kettering Cancer Center’s (MSKCC)
DrugAbacus: “DrugAbacus provides a way of
thinking about how to price drugs. This interactive
tool takes more than 50 cancer drugs and lets you
Table 1 Common themes and conclusions identified in review
of literature on AE cost determination
Key Observations from Literature Review on AE Cost Determination
Frequent use of modeled and patchworked datasets. AE cost
estimation studies relied on modeled data, assumptions about patient
experience, and/or data pooled from diverse sources and studies in 96%
of studies reviewed.
Reliance on randomized control trials (RCT) as source of data on
frequency and nature of AEs in patient population. RCTs from Phase
II, III, and/or IV clinical trials served as the primary data source for
frequency and nature of the AEs in these cost studies (~ 70% of studies).
A small percentage (19%) of studies used ‘postmarket’ databases such as
the Premier Perspective Database (e.g., data from 600 U.S. hospitals) as a
resource to identify the frequency and nature of AEs requiring clinical
care.
Limited consideration of non-severe adverse events. For cost
estimation studies utilizing clinical trials, the vast majority incorporated
only those AEs that were reported as severe (grade 3 or grade 4). Note:
Consensus Toxicity Criteria for Adverse Events (CTC-AE), includes a
standardized list of outcomes and symptoms in oncology trials and
includes a severity grading scale associated with these effects [93]. Grade 1
is the least severe and can include outcomes like fatigue. Grade 4 indicates
very severe toxicities (like liver failure), and grade 5 denotes death
associated with an adverse treatment effect.
Near absence of contemporary patient-reported data on quality of
life impacts. Only one of the 27 studies (4%) identified in this review
incorporated direct measures of QoL into the cost assessment [71] via
surveys of participating patients. About half of the math modeling
studies used “utility factors” to incorporate QoL-related adjustments.
These adjustment factors appear to have been based primarily on Euro-
Qol 5D surveys and time trade-off (TTO) surveys conducted in prior clin-
ical most of which were conducted in the early 2000s. Discussion of the
relevance of the utility factors selected was minimal to absent.
Absent or internally inconsistent demographic information. The
relationship between the target patient demographics (e.g., age, gender,
race, geography, etc.) and the demographic from whom the cost or AE
incidence data was derived was missing/or incongruous in ~ 80% of
studies reviewed.
Limited consideration of patient-relevant indirect costs.
Incorporation of elements such as lost wages for time off work,
caregiver costs, and lost future employment potential were only
incorporated in 25% of the reviewed studies. An exclusive focus on
direct costs (defined as cost of a hospital or physician visit associated
with a treatment-related adverse event) in modeled or cumulative cost
estimates was noted in~ 75% of studies reviewed.
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compare the company’s price to one based on value”
[97].
 National Comprehensive Cancer Center Network
(NCCN) Evidence Blocks: “The goal is to provide the
health care provider and the patient information to
make informed choices when selecting systemic
therapies based upon measures related to treatment,
supporting data, and cost” [101].
A novel comparative summary of the frameworks with
respect to incorporation of AE and QoL specifically is
provided here (Table 2). It is notable that AE/toxicity
data (typically from published clinical trial data) are in-
corporated in all of the frameworks as a means of char-
acterizing this key aspect of treatment choice.
Although the construct of these five frameworks and
their intended audiences have been compared previ-
ously, this study further characterizes the current and
future utility of these frameworks with respect to inte-
gration of AEs and patient reported outcome (PRO) in-
formation [102–106]. Specifically, this review addressed
the following: What recommendations have been pro-
moted to improve the quality and/or relevance of
AE-related input data for value frameworks?
Search strategy
A systematic literature search was conducted using the
following databases: PubMed, Web of Science, and
CINAHL Plus with Full Text. Additional studies were
identified through a manual search of references in rele-
vant articles (snowballing). The search terms, exclusion
criteria, and PRISMA diagram detailing the literature
procurement and review strategy are available as Add-
itional file 1: Tables S8-S9, and Additional file 3: Figure
S2.
Results
This review captures recommendations and perspectives
from a total of 17 peer-reviewed publications [95, 102–
104, 106–118]. The reviewed studies were almost evenly
split between those including a narrative/qualitative
comparison of different frameworks and those incorpor-
ating case study/quantitative comparisons across differ-
ent value frameworks. With limited exceptions, all
studies provided perspectives on opportunities to im-
prove either the construct of the framework or some as-
pect of the input data.
The most commonly identified areas for improvement,
in relation to the nature and quality of input data used
Table 2 Comparison of five major value frameworks regarding the use of toxicity and adverse event approaches
Framework Objective Efficacy &
safety data
sources
Scoring/output Efficacy/safety-related input data
ASCO Inform joint decision
making by patients
and clinicians
Clinical trials • Generates a single composite scored called
the ‘Net Health Benefit’ (NHB)
• Uses different algorithms for advanced
disease vs adjuvant setting
• Uses AE data drawn from clinical trials.
• Can incorporate adjustments for QoL,
treatment-free interval, improvement in cancer
symptoms. Can score for disease free survival
(cure) or progression free survival.
ESMO Inform public policy,
clinical guidelines,
and direct clinical
care
Clinical trials • Semi-quantitative process results in assign-
ment of letter score (A–C) for adjuvant
setting
• Semi-quantitative process results in assign-
ment of number score (1–5) for advanced
disease
• Can score for disease free survival (cure) or
progression free survival.
• “Toxicity” and QoL rating incorporated.
NCCN Inform joint decision
making by patients
and clinicians
Clinical trial
and expert
opinion
• Assigns a series of Evidence Block Scores (5-
point high score, 1-point low score) cat-
egories such as toxicity, efficacy, cost, etc.
• Incorporates a range of both qualitative and
quantitative inputs that are qualitatively
synthesized via expert panels.
ICER Provide synthesis for
use by policymakers
and payers/
formularies
Clinical trials,
econometric
studies
• Compares standard intervention and new
treatment relative to short term costs and
longer-term healthcare system burdens and
benefits.
• Includes quality-adjusted life year scoring
factors.
• Serious AEs are factored into scoring
• Ability to work while on therapy factored into
scoring
DrugAbacus Provide pricing data
for use by
policymakers and
payers
Drug safety
/efficacy data
as provided to
FDA
• Factors benefits and burdens of treatment
into a new “price” based on Abacus
algorithm relative to industry-specified
price.
• Scores improved survival rate
• Serious AEs (e.g., grade 3 or greater)
incorporated into scoring
• The probability that a patient discontinues
treatment because of toxicity is considered in
scoring
• Treatment novelty, R&D cost, health burden
and treatment duration
Table 2 was modified from tables previously published in Chandra et al. (2016), Cohen, Anderson, & Neumann (2017), and Schnipper & Bastian (2016). AE, adverse
event; ASCO, American Society of Clinical Oncology; DFS, disease-free survival; ESMO, European Society for Medical Oncology; FDA, U.S. Food and Drug
Administration; ICER, Institute for Clinical and Economic Review; NCCN, National Comprehensive Cancer Network; NHB, net health benefit; PFS, progression-free
survival; QALY, quality-adjusted life-year; QoL, quality of life; R&D, research and development. See Definition section for explanation of terms
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to populate these frameworks, were divided into eight
categories per Table 3. No one recommendation or
modification to improve the relevance of the frameworks
for informing patient QoL was cited by all the publica-
tions. However, the need for more robust and/or detailed
safety and toxicity data inclusion in these frameworks
was the most common recommendation identified.
Additionally, several studies called for more over-
arching changes to clinical trial design with regard to
patient inclusion criteria, duration, outcomes mea-
sures, and so forth [102, 110, 112, 115, 119]. The de-
tails of such modifications were not thoroughly
addressed in these publications and are the subject of
much discussion elsewhere, but they could have sig-
nificant impact on the type of AE data generated in
the future [120].
Although not the focus of this review, it is import-
ant to note that many of the publications also called
for broad-based improvements in the design or use of
the frameworks themselves. Specifically, enhanced
clarity and transparency as to the intended audience
for the framework outputs [103, 104, 110, 111, 121]
and improved guidance to enhance reproducibility
were common recommendations [107, 108, 111, 114,
119, 122].
Limitations of these reviews
These reviews have a number of limitations. Because
this study sought to assess impact in a U.S. healthcare
context, economically based health technology assess-
ments (HTAs) as required in Europe and several
other regions to assess the cost-benefit of novel ther-
apies were not incorporated. HTA studies are numer-
ous and relatively standardized in their approaches
and assumptions. Although HTAs relate only to
single-payer healthcare systems that do not match the
current U.S. multi-payer profile, they could provide
potentially useful sources for methodological compari-
sons. Because selected HTAs also include quality of
life (QALY) assessment in their economic evaluation
of the cost-benefit of the therapy they can also
provide a resource in this regard for financial
valuation-focused queries.
Similarly, the term “comparative effectiveness” was
intentionally excluded in order to exclude the “compara-
tive effectiveness research” literature. Although these
studies do sometimes include cost estimates of AEs,
their focus is exclusively on the differential/comparator
between two similar therapies and thus the total cost of
AEs (the focus of this review) is rarely measured [67].
Prior systematic reviews of AE effect cost assessments
have noted this limitation in the use of comparative ef-
fectiveness studies and thus they were excluded from
this search. This review also did not compare the abso-
lute value of reported costs across studies because of the
variable drugs, study designs, timescales, and patient
populations assessed.
Additionally, the breadth of U.S.-based studies in
this review provides an opportunity to characterize a
diverse range of methods, but it also means that com-
parison across studies at a granular level is limited.
Future studies might focus on a single drug class or
cost assessment approach to allow for more focused
cross-study comparison of input data and conclusions.
Additionally, more comprehensive insights into meth-
odological and data input assumptions across these
studies could be gleaned by review of key underlying
studies cited by the studies reviewed here.
Table 3 Literature-based Recommendations for Improvement of Inputs to Existing Frameworks
Suggested improvement No of
Articles
References
Need improvements to clinical trial design to obtain more patient-relevant data 5 of 17
(29%)
[102, 110, 112, 115, 119]
Need cost data that reflect full cost of care/treatment (not just drug costs) 5 of 17
(29%)
[104, 108, 112, 116, 117]
Frameworks should incorporate patient-reported outcome data (via inclusion of patient-reported outcomes
in clinical trials)
4 of 17
(24%)
[103, 112, 119, 138]
Frameworks should incorporate data from sources other than clinical trials (e.g., observational studies) 3 of 17
(18%)
[102]
Frameworks should incorporate more robust and/or detailed safety and/or toxicity data 7 of 17
(41%)
[103, 104, 108, 112, 115,
116]
Frameworks should use integrated quality of life measures in lieu of safety data 1 of 17
(6%)
[117]
Frameworks should incorporate more longitudinal data 2 of 17
(12%)
[102, 103]
Frameworks should engage patients in the data evaluation and input process 3 of 17
(18%)
[102, 103, 110]
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Synthesis of results of literature evaluations
Characterizing the risk:benefit profile of an antineoplas-
tic therapy requires integration of a complex and
heterogenous mix of pharmacologic, economic, actuarial,
ethical, and sociologic factors. The complementary lit-
erature searches described here illustrate progress to-
ward this integration. However, with respect to use and
integration of AE information, several common themes
and areas for improvement were identified. These broad
areas of commonality and their relevance to the field of
cardio-oncology are discussed in detail below.
Challenges in use of clinician-reported adverse event data
derived from randomized controlled trials
In both the purely economic and integrated value frame-
work approaches reviewed here, Phase II–III RCTs serve
as the primary source of data on the incidence of
treatment-related adverse effects. Almost 70% of the cost
studies reviewed here (and even more of the value
frameworks) rely heavily or exclusively on RCT data to
inform toxicity/safety. RCTs are accepted,
well-controlled studies with defined inclusion criteria
and dosing and monitoring strategies. However, many of
the studies reviewed here noted the limitations of RCTs
for purposes of providing pragmatic patient decision
support (i.e., high internal validity but low external valid-
ity). These limitations include the following:
 Population Mismatch. Populations engaged in
RCTs tend to be “healthier” and with fewer
comorbidities than the average patient population
on the therapy [123]. The frequency and severity of
AEs in the clinical trial population may be under-
representative of AE incidence and severity in the
broader patient population and may thus lead to an
underestimation of overall cost and incidence bur-
den [124].
 Severity Skew. The type of AEs recorded in Phase
II/III trials specifically have been reported to skew
toward a focus on only high-grade (grade 3 or 4)
toxicities, pool toxicities of varying severity, include
both quantitative and qualitative evaluations, and/or
misgrade toxicities [125, 126]. Thus, it is possible
that a significant pool of AE data may be systematic-
ally excluded from these evaluations. Even when
lower-grade toxicities are reported in RCTs, this re-
view demonstrates an almost exclusive (~ 80%) use
of the high-grade AE data for purposes of cost mod-
eling or in value frameworks. The ASCO framework
was recently revised to allow for incorporation of
grade 1 and 2 AEs if they occur at sufficient fre-
quency [95]. Given the tendency to under-report
low-grade AEs in trials and published concerns
about “unclear reporting of lower-grade toxicities,”
the potential for these endpoints to usefully inform
patient/clinician choice via integrative tools is lim-
ited at present [127–129].
 Limited Duration. The timeframe of study in an
RCT provides a limited window (months to ~
4 years) for capture of treatment-related effects. This
limitation is of particular concern in the cardio-
oncology arena as many relevant cardiac AEs do not
manifest for many years after the closure of therapy
and/or persist for many years after therapy has been
completed. As such, RCTs may provide an incom-
plete picture of impact.
 Uncertain Naming Conventions. The evolving
nature of the CTCAE ontology used to record and
grade AEs creates a “moving target.” The number of
terms has expanded by a factor of 4 in the last
20 years. Thus, the version of CTCAE (or other
ontology) can have a significant impact on the
nature, naming, and overall reported incidence of
AEs used in cost evaluation studies. Several clinical
specialty areas that address common antineoplastic
treatment-related AEs (e.g., rheumatology) have de-
veloped their own AE ontologies and grades to re-
flect the more nuanced perspective of a specialist
[130]. Experts have noted that the recording of AEs
by non-specialists can result in non-specific calls
such as ‘cardiac-general’ with no detail about the na-
ture of the cardiotoxicity [127]. Without additional
and well-sourced granularity in these toxicity re-
ports, it will be challenging for regulators, clinicians,
and patients to appropriately calibrate expectations
and supportive care needs. Future AE incidence bur-
den evaluations would benefit from a thorough
characterization of the ontological and inclusion/ex-
clusion framework that guided the capture of their
core input data and its potential impact on
outcomes.
 Repurposing. RCTs are designed for evaluation by
regulatory scientists for purposes of drug approval
decision making. Although they are routinely used
in this manner, these studies are not specifically
designed to generate information to be used by
clinicians or patients with regard to individual
therapeutic or supportive care pathways.
Alternatives to the use of clinician-reported adverse event
data derived from randomized controlled trials
Although of many of the studies reviewed here identified
one or more shortcomings of RCT-derived AE data, only
three (17%) of the publications on value frameworks
proposed the future incorporation of data from sources
outside of an RCT setting [102–104]. Similarly, only 18%
of the cost models used data sources outside of RCTs
for AEs [72, 74, 75, 87, 88]. This trend points to a simple
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fact: while it is relatively easy to identify weaknesses in
the RCT as a data source for informing patient
value-choices, the identification of viable alternatives or
complements is quite challenging. As illustrated in Fig. 2,
the articles reviewed here identified potential opportun-
ities for improvement via 1) increased use of PRO mea-
sures; and/or 2) increased use of observational/
surveillance/EHR data sets.
Patient-reported outcomes and quality of life metrics
As patients and clinicians seek both enhanced
progression-free survival as well as positive QoL, the in-
clusion of PRO data and/or QoL metrics into the valu-
ation (economic or otherwise) of antineoplastic therapy
regimes has gained prominence in recent years. The
sources of data on QoL in the studies in this review in-
cluded Markov model-based utility factors derived from
EuroQol 5-D surveys, direct patient surveys that col-
lected data on quality metrics, and clinician judgement
on impact of patient QoL. The ICER and ESMO frame-
works include QoL through incorporation of a QALY
metric. ASCO uses palliation of symptoms and
treatment-free intervals as a proxy for QoL measures.
However, the relevance of these input data are uncertain,
as some of the QoL adjustment factors used in these
economic evaluations were derived from assessments
conducted as many as 20 years ago and some included
undocumented “value judgements” based on clinician
experience [77, 90, 99, 131]. Additionally, the way in
which these data were integrated into the value assess-
ments described in this review varied from probabilistic
modeling approaches to awarding of ad hoc “bonus
points.” It is beyond the scope of this review to assess
the relative strengths and weakness of each of these ap-
proaches. However, this review does reveal that the prac-
tice of including PRO or QoL metrics into integrated
value assessments relating AEs and treatment choice is
neither systematic nor standardized.
Undoubtedly, this is a challenging space. The tools
and perspectives on the extent to which QoL or PROs
can or should be leveraged routinely in trials or clinical
practice are evolving rapidly [132]. We also know that
there are often disparities between patient and clinical
perspectives on the scope and nature of AE burden
[133]. Thus, the future use of tools to assess AEs from
the perspective of the patient may provide novel insights
into the overall physical, logistical, and financial burden
of antineoplastic therapy. As patients or survivors ex-
periencing cardiac AEs associated with their curative
therapy are likely to experience impacts on their ability
to work, exercise, engage in recreation, etc., QoL consid-
erations are expected to be of significant relevance to
therapy adherence and outcome.
Increased use of observational/surveillance/electronic
health record data sets
Collectively, the publications reviewed here offered very
limited recommendations for or examples of incorporating
AE data from sources other than RCTs. The few prospect-
ive or patient-database driven economic evaluation studies
in this review appear to provide a clearer picture of the
frequency and nature of AEs, although the less controlled
setting can make an estimation of treatment-attributable
costs more challenging [72, 74, 75, 87, 88]. None of the
value frameworks utilize non-RCT data this time. This
phenomenon reflects the “gold standard” status of RCTs
for driving drug safety and efficacy decisions and lack of
standards for use of other data sources. Increasingly, the
potential for observational studies and large-scale health-
care databases to provide reliable data on a broad range of
patient adherence practices, outcomes measures, and poly-
pharmacy/comorbidity situations has been recognized
[134–136]. Future developments in this arena will require
Fig. 2 Summary of recommendations from literature review for improving adverse event data relevance in value frameworks
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a thoughtful confrontation of the tension between uncon-
trolled data derived directly from patient care settings and
the value of nuanced and realistic representation of patient
experiences.
The costs
A detailed discussion of cost estimation methodology is
not the focus of this review. However, the link between
value decisions, cost calculations, and AE-related im-
pacts is an important component of this discussion.
Some economic evaluation studies reviewed here
attempted to include all treatment-related costs that the
author could identify (drug cost, hospital cost, doctor
visits, monitoring and testing, over-the-counter drugs, ad-
ministration fees, lost work cost, caregiver costs, future
employment potential costs, etc.; e.g., Sorensen et al.,
2012), whereas others addressed only the primary cost of
treating the AE in a hospital setting [72]. Cost metrics
used within the current value framework structures were
equally variable but are largely restricted to cost of the
drug and/or primary treatment visits. Many of the ana-
lyses reviewed here specifically recommended that future
iterations of these models should incorporate the full cost
of care including AEs [104, 108, 116, 117, 137] This
recommendation, while sound on its face, begs the
questions of what constitutes the burden of antineoplastic
therapy-related AEs, who carries these burdens, and
how broadly should costs be captured. It also speaks
to the importance of transparent discussion regarding
the stakeholders to whom the value assessment is
intended to apply.
The patients
Patients are at the core of all of the value discussions
and treatment choices described here. Surprisingly,
nearly a third of the economic valuation studies
reviewed here failed to provide clear demographic infor-
mation on either the patient population that constituted
their input data or the patient population to whom their
model/valuation was intended to characterize or both
[80, 82, 86, 89, 100, 111, 114]. In fact, none of the pri-
mary value frameworks described in Table 2 or any of
the publications about these frameworks (as reviewed
here) included a discussion of patient demographics
other than a focus on patients with a specific disease.
Even for those studies where the patient population was
clearly defined, there were sometimes disconnects be-
tween the target population and the patient group that
served as primary data on AEs, QoL metrics, and/or cost
estimations. For example, ~ 40% of the studies reviewed
here utilized cost data from Medicare, although only ~
20% characterized their study population as older than
age 60. Such disconnects may be inevitable given the
limited availability of data in this space. However, the
relevance of frameworks for informing patient choice
and treatment decisions could be enhanced with greater
clarity around these limitations and their potential im-
pacts on the way in which AE-related impacts are syn-
thesized and subsequently interpreted.
Improving the use of AEs to inform assessments
of treatment impact on patients & survivors
We began these reviews by questioning whether current
data capture and integration systems are improving in
their ability to anticipate and proactively support AEs
such as treatment-related cardiotoxicity. On the one
hand, these reviews reveal a growing focus on the inter-
ests of patients, payers, clinicians, regulators, and drug
developers in making informed choices around the use
of antineoplastic therapies that enhance progression-free
survival with minimal impact on overall QoL. However,
it is also clear that our current means to assess and
synthesize the scale and impact of this burden on pa-
tients, survivors, and the system at large remains insuffi-
cient in many ways. Much of the input data used in
current integrative efforts to describe AE incidence and
severity is of limited or unclear relevance for the diverse,
long-lived, and comorbid patient population that is rap-
idly growing around the world. We observed an overall
lack of clarity around how to best use AE data to inform
cancer patient care and cancer therapy safety assessment
– particularly in long term cancer therapy and survivor-
ship contexts of relevance to the cardio-oncology field.
This uncertainty suggests that we may continue to
struggle with the proactive identification of
treatment-related cardiac (as well as other) effects that
take years to fully manifest or to be potentiated. Indeed,
our ability to effectively capture the scope and impact of
relatively rapid onset (but not highly severe) AEs appears
limited as well.
Moving forward, limitations around the data, as well
as the implications of those limitations in terms of how
they may affect the patient’s lived experience and quality
of life should be made more evident to patients,
clinicians, and other stakeholders when possible. This
communication is essential in supporting more
person-centered cancer care planning and shared deci-
sion making that helps align treatments with patients’
values and preferences. While such information may not
immediately influence treatment decisions, it can have
important downstream effects. First, it can seed critical
exchanges around supportive care, quality of life prior-
ities and expectations, and health monitoring. These ex-
changes have the potential to positively influence patient
outcomes. Second, as patients and their family caregivers
become more educated about AE’s, they have the oppor-
tunity to leverage their influence as primary stakeholders
to demand improvements that prioritize information
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quality, access to appropriate supportive care and moni-
toring, and AE-reducing treatment options in the future
for maximizing both quantity and quality of life.
Conclusion
The current breadth of approaches for integrating AE,
QoL, efficacy, and cost can be viewed as a signal of the
public health and cancer communities’ commitment to
and investment in these issues. However, the continued
reinvention of these approaches also suggests that the
complement of current efforts may not be adequately
synergistic or fit for purpose. While the development of
the cardio-oncology field has offered some important
visibility to the impact of treatment-related AE on pa-
tient survival and QoL, it does not appear to be associ-
ated with any broad systemic transformations in
AE-relevant data collection or use. The biomedical com-
munity has made incredible progress in treatments
resulting in step-changes in progression free survival.
However, the biomedical and public health communities
have not adequately transitioned to AE-related informa-
tion collection and use frameworks that fully aligns with
this increasing therapeutic efficacy and survivorship. Fu-
ture research and associated action is needed to ensure
that understandable and reliable information about long
term outcomes can be made more relevant and access-
ible for a growing population of long-term survivors and
the stakeholders who seek to support them.
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